Alzheimer's R&D: Tweaking Venture's Risk-Reward Ratio
This article was originally published in Start Up
Executive Summary
Building Alzheimer's-focused companies remains difficult, in part because venture capital remains scarce. But advancese in diagnostic and imaging tools, improved means of measuring the impact of drugs on cognition, and a better understanding of therapeutic targets mean investment risks are improving, say some executives and VCs. Can Alzheimer's attract more mainstream VC investment and pay off with more lucrative deals like Pfizer's acquisition of Rinat?
You may also be interested in...
Overcoming Disaster: What Biotechs Do When A Lead Asset Fails
Drug candidates fail at an alarming rate. For biotechs that seemingly have their entire future - and tens of millions of investor dollars - tied up in one compound or one clinical trial, failure of a lead asset can mean certain, sudden death. Meet four small companies that had another plan.
Overcoming Disaster: What Biotechs Do When A Lead Asset Fails
Drug candidates fail at an alarming rate. For biotechs that seemingly have their entire future - and tens of millions of investor dollars - tied up in one compound or one clinical trial, failure of a lead asset can mean certain, sudden death. Meet four small companies that had another plan.
Lilly Tries to Buy Time
Facing a steep patent cliff and a dearth of late-stage drugs, Lilly is slashing expenses, reorganizing R&D, and hoping to attract investors to share the risks and rewards of pipeline development. Will these moves be enough?